Target Information
Target General Information | Top | |||||
---|---|---|---|---|---|---|
Target ID |
T03871
(Former ID: TTDR01356)
|
|||||
Target Name |
H-ras messenger RNA (HRAS mRNA)
|
|||||
Synonyms |
p21ras (mRNA); cHras (mRNA); c-H-ras (mRNA); Transforming protein p21 (mRNA); HaRas (mRNA); Ha-Ras (mRNA); H-Ras-1 (mRNA); GTPase HRas, Nterminally processed (mRNA); GTPase HRas (mRNA)
Click to Show/Hide
|
|||||
Gene Name |
HRAS
|
|||||
Target Type |
Discontinued target
|
[1] | ||||
Disease | [+] 1 Target-related Diseases | + | ||||
1 | Solid tumour/cancer [ICD-11: 2A00-2F9Z] | |||||
Function |
Ras proteins bind GDP/GTP and possess intrinsic GTPase activity. Involved in the activation of Ras protein signal transduction.
Click to Show/Hide
|
|||||
BioChemical Class |
mRNA target
|
|||||
UniProt ID | ||||||
Sequence |
MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAG
QEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHQYREQIKRVKDSDDVPMVLVGNKCDL AARTVESRQAQDLARSYGIPYIETSAKTRQGVEDAFYTLVREIRQHKLRKLNPPDESGPG CMSCKCVLS Click to Show/Hide
|
Cell-based Target Expression Variations | Top | |||||
---|---|---|---|---|---|---|
Cell-based Target Expression Variations |
References | Top | |||||
---|---|---|---|---|---|---|
REF 1 | A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer. Clin Cancer Res. 2003 Jan;9(1):115-23. | |||||
REF 2 | US patent application no. 7,425,545, Modulation of C-reactive protein expression. | |||||
REF 3 | US patent application no. 5,965,722, Antisense inhibition of ras gene with chimeric and alternating oligonucleotides. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.